Blastomycosis, unspecified
ICD-10 B48.1 is a billable code used to indicate a diagnosis of blastomycosis, unspecified.
Blastomycosis is a systemic fungal infection caused by the dimorphic fungus Blastomyces dermatitidis, primarily affecting the lungs but can disseminate to other organs. The infection is endemic in certain regions, particularly in North America, where exposure to the fungus occurs through inhalation of spores from contaminated soil or decaying organic matter. Symptoms may range from mild respiratory issues to severe pneumonia, and systemic manifestations can include skin lesions, bone pain, and neurological symptoms. Diagnosis is typically confirmed through culture, serology, or histopathological examination. Treatment often involves antifungal medications such as itraconazole or amphotericin B, especially in immunocompromised patients who are at higher risk for severe disease. The unspecified designation indicates that the specific site or severity of the infection has not been documented, which may complicate treatment decisions and coding accuracy.
Detailed clinical history, laboratory results, and treatment plans.
Patients presenting with respiratory symptoms and a history of exposure to endemic areas.
Need for thorough documentation of immunocompromised status and treatment response.
Pulmonary function tests, imaging studies, and symptom assessments.
Patients with chronic cough, fever, and weight loss.
Documentation of differential diagnoses and response to antifungal therapy.
Used when a fungal infection is suspected and culture is needed for diagnosis.
Document the reason for the culture and any prior treatments.
Infectious disease specialists may require additional lab results to support diagnosis.
Common symptoms include cough, fever, night sweats, weight loss, and skin lesions. Symptoms can vary based on the severity of the infection and the patient's immune status.
Diagnosis is typically made through clinical evaluation, imaging studies, and laboratory tests such as culture or serology to confirm the presence of Blastomyces dermatitidis.
Treatment usually involves antifungal medications such as itraconazole or amphotericin B, depending on the severity of the infection and the patient's overall health.
